In the preclinical stage, the individual may display no signs or symptoms of parkinsonism, but available testing can detect some changes in physiology (e.g., dopaminergic transmission deficit through dopamine transporter scans or alpha-synuclein aggregation through skin biopsies). Here, SLC6A3 is linked to Parkinson disease.